Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

Regulatory milestones

Acura Pharmaceuticals Inc. (NASDAQ:ACUR) gained $0.63 (16%) to $4.50 on Monday after FDA approved an NDA from partner Pfizer Inc. (NYSE:PFE) for Oxecta oxycodone (formerly Acurox oxycodone without niacin) to manage acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

Oxecta uses Acura's Aversion abuse-deterrent technology. The approval triggered a $20 million milestone payment from Pfizer, which expects to launch the product next half. Acura was up $0.23 to $4.10 on the week.

Amgen Inc. (NASDAQ:AMGN) dipped $0.89 to $57.04 on Friday after FDA modified the black box warning and recommended more conservative dosing for erythropoiesis-stimulating agents (ESAs) used to treat anemia in chronic kidney disease (CKD) patients, citing increased risk of cardiovascular

Read the full 1195 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers